[go: up one dir, main page]

FR23C1013I1 - BINDING MOLECULES FOR BCMA AND CD3 - Google Patents

BINDING MOLECULES FOR BCMA AND CD3

Info

Publication number
FR23C1013I1
FR23C1013I1 FR23C1013C FR23C1013C FR23C1013I1 FR 23C1013 I1 FR23C1013 I1 FR 23C1013I1 FR 23C1013 C FR23C1013 C FR 23C1013C FR 23C1013 C FR23C1013 C FR 23C1013C FR 23C1013 I1 FR23C1013 I1 FR 23C1013I1
Authority
FR
France
Prior art keywords
bcma
binding molecules
molecules
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR23C1013C
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47388493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR23C1013(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR23C1013I1 publication Critical patent/FR23C1013I1/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR23C1013C 2011-11-15 2023-02-22 BINDING MOLECULES FOR BCMA AND CD3 Active FR23C1013I1 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201161560149P 2011-11-15 2011-11-15
US201161560178P 2011-11-15 2011-11-15
US201161560162P 2011-11-15 2011-11-15
US201161560144P 2011-11-15 2011-11-15
US201161560183P 2011-11-15 2011-11-15
US201261651474P 2012-05-24 2012-05-24
US201261651486P 2012-05-24 2012-05-24
PCT/EP2012/072699 WO2013072406A1 (en) 2011-11-15 2012-11-15 Binding molecules for bcma and cd3

Publications (1)

Publication Number Publication Date
FR23C1013I1 true FR23C1013I1 (en) 2023-04-14

Family

ID=47388493

Family Applications (1)

Application Number Title Priority Date Filing Date
FR23C1013C Active FR23C1013I1 (en) 2011-11-15 2023-02-22 BINDING MOLECULES FOR BCMA AND CD3

Country Status (40)

Country Link
US (7) US9598500B2 (en)
EP (5) EP3623385A1 (en)
JP (5) JP6378087B2 (en)
KR (4) KR102062231B1 (en)
CN (3) CN104169300A (en)
AP (1) AP2014007529A0 (en)
AR (1) AR088883A1 (en)
AU (1) AU2012327203A1 (en)
BR (2) BR112014010940A2 (en)
CA (2) CA2850591A1 (en)
CL (1) CL2014001254A1 (en)
CY (1) CY1122543T1 (en)
DK (1) DK2780375T3 (en)
EA (2) EA028162B1 (en)
EC (2) ECSP14004829A (en)
ES (2) ES2749451T3 (en)
FR (1) FR23C1013I1 (en)
GE (1) GEP20186928B (en)
HR (1) HRP20191697T1 (en)
HU (1) HUE046682T2 (en)
IL (3) IL232603B (en)
LT (1) LT2780375T (en)
MA (2) MA35450B1 (en)
ME (1) ME03521B (en)
MX (2) MX2014005851A (en)
MY (1) MY189544A (en)
PE (1) PE20141564A1 (en)
PH (2) PH12014501076A1 (en)
PL (1) PL2780375T3 (en)
PT (1) PT2780375T (en)
RS (1) RS59373B1 (en)
SG (4) SG11201400671YA (en)
SI (1) SI2780375T1 (en)
SM (1) SMT201900627T1 (en)
TN (2) TN2014000097A1 (en)
TW (1) TWI679212B (en)
UA (1) UA116766C2 (en)
UY (2) UY34453A (en)
WO (2) WO2013072406A1 (en)
ZA (1) ZA201401615B (en)

Families Citing this family (188)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX338038B (en) * 2008-10-01 2016-03-30 Amgen Res Munich Gmbh Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody.
TWI679212B (en) * 2011-11-15 2019-12-11 美商安進股份有限公司 Binding molecules for e3 of bcma and cd3
EP2817338B1 (en) 2012-02-24 2017-07-26 AbbVie Stemcentrx LLC Dll3 modulators and methods of use
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
TW201425336A (en) 2012-12-07 2014-07-01 Amgen Inc BCMA antigen binding proteins
EP2762496A1 (en) * 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
WO2014122143A1 (en) * 2013-02-05 2014-08-14 Engmab Ag Method for the selection of antibodies against bcma
HRP20191169T1 (en) 2013-02-22 2019-10-04 Abbvie Stemcentrx Llc Novel antibody conjugates and uses thereof
AR095374A1 (en) * 2013-03-15 2015-10-14 Amgen Res Munich Gmbh UNION MOLECULES FOR BCMA AND CD3
SG11201601424PA (en) 2013-08-28 2016-03-30 Stemcentrx Inc Site-specific antibody conjugation methods and compositions
DK3055327T3 (en) * 2013-10-09 2019-03-11 Res Found Dev Monoclonal OLFML-3 Antibodies and Uses thereof
GB201317929D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
GB201317928D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Molecule
CA2945486A1 (en) 2014-02-07 2015-08-13 Mcmaster University Trifunctional t cell-antigen coupler and methods and uses thereof
US10308721B2 (en) 2014-02-21 2019-06-04 Abbvie Stemcentrx Llc Anti-DLL3 antibodies and drug conjugates for use in melanoma
CN106414502A (en) * 2014-02-27 2017-02-15 Ucl商务股份有限公司 April variants
AU2015248956B2 (en) * 2014-04-14 2020-06-25 Cellectis BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy
MX2016017393A (en) 2014-07-01 2017-09-05 Pfizer Bispecific heterodimeric diabodies and uses thereof.
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
US20170306044A1 (en) * 2014-10-09 2017-10-26 Engmab Ag Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer
EP3023437A1 (en) * 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
RS60615B1 (en) 2014-11-20 2020-08-31 Hoffmann La Roche Common light chains and methods of use
MY184889A (en) 2014-11-20 2021-04-29 Hoffmann La Roche T cell activating bispecific antigen binding molecules
EP3029068A1 (en) 2014-12-03 2016-06-08 EngMab AG Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
PH12017501040B1 (en) 2014-12-05 2023-07-05 Eureka Therapeutics Inc Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
SG10201901707QA (en) * 2014-12-05 2019-03-28 Memorial Sloan Kettering Cancer Center Antibodies targeting b-cell maturation antigen and methods of use
KR102626448B1 (en) * 2015-02-24 2024-01-19 더 유니버시티 오브 브리티시 콜롬비아 Continuous flow microfluidic systems
AU2016248946C1 (en) 2015-04-13 2024-10-17 Pfizer Inc. Therapeutic antibodies and their uses
MY188432A (en) 2015-04-13 2021-12-08 Pfizer Chimeric antigen receptors targeting b-cell maturation antigen
HRP20240971T1 (en) * 2015-05-13 2024-10-25 Ablynx Nv POLYPEPTIDES FOR T-CELL RECRUITMENT BASED ON CD3 REACTIVITY
PL3298033T5 (en) * 2015-05-18 2023-10-30 TCR2 Therapeutics Inc. Compositions and medical applications for TCR reprogramming using fusion proteins
CN111234027A (en) 2015-05-21 2020-06-05 哈普恩治疗公司 Trispecific binding proteins and methods of use
TWI796283B (en) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Antibody constructs for msln and cd3
TWI744242B (en) * 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Antibody constructs for egfrviii and cd3
TWI829617B (en) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Antibody constructs for flt3 and cd3
SMT202000139T1 (en) * 2015-08-03 2020-05-08 Engmab Sarl Monoclonal antibodies against human b cell maturation antigen (bcma)
SG10201913625XA (en) 2015-08-07 2020-03-30 Imaginab Inc Antigen binding constructs to target molecules
CN105384825B (en) * 2015-08-11 2018-06-01 南京传奇生物科技有限公司 A kind of bispecific chimeric antigen receptor and its application based on single domain antibody
CN108350076B (en) 2015-08-17 2022-06-07 詹森药业有限公司 Anti-BCMA antibodies, bispecific antigen binding molecules that bind BCMA and CD3 and uses thereof
SG10201912570UA (en) 2015-09-24 2020-02-27 Daiichi Sankyo Co Ltd Anti-garp antibody
CA3006058A1 (en) 2015-11-25 2017-06-01 Visterra, Inc. Antibody molecules to april and uses thereof
TWI797073B (en) * 2016-01-25 2023-04-01 德商安美基研究（慕尼黑）公司 Pharmaceutical composition comprising bispecific antibody constructs
DK3411402T3 (en) * 2016-02-03 2022-02-07 Amgen Res Munich Gmbh BCMA AND CD3 BISPECIFIC T-CELL INVOLVING ANTIBODY CONSTRUCTIONS
EA039859B1 (en) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Bispecific antibody constructs binding egfrviii and cd3
CR20180418A (en) 2016-02-03 2019-01-15 Amgen Res Munich Gmbh BISPECPIFYING ANTIBODY STRUCTURES FOR PSMA AND CD3 THAT ARE LINKED TO T-CELLS
FI3433280T3 (en) 2016-03-22 2023-06-06 Hoffmann La Roche Protease-activated t cell bispecific molecules
WO2017173349A1 (en) 2016-04-01 2017-10-05 Kite Pharma, Inc. Bcma binding molecules and methods of use thereof
US10550184B2 (en) 2016-04-11 2020-02-04 The Trustees Of Columbia University In The City Of New York Humanized anti-rage antibody
JP7101621B2 (en) 2016-05-20 2022-07-15 ハープーン セラピューティクス，インク． Single domain serum albumin binding protein
EP3461261B1 (en) 2016-05-20 2025-07-09 Harpoon Therapeutics, Inc. Single chain variable fragment cd3 binding proteins
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
WO2017223111A1 (en) * 2016-06-21 2017-12-28 Teneobio, Inc. Cd3 binding antibodies
WO2018014260A1 (en) * 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
JP7109789B2 (en) 2016-08-02 2022-08-01 ティーシーアール２ セラピューティクス インク． Compositions and methods for TCR reprogramming using fusion proteins
MX2019002967A (en) * 2016-09-14 2019-07-04 Teneobio Inc CD3 BINDING ANTIBODIES.
EP3445787B1 (en) 2016-10-07 2020-12-02 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
KR102687833B1 (en) * 2016-11-02 2024-07-24 브리스톨-마이어스 스큅 컴퍼니 Combination use of dual specific antibodies and immunological drugs against BCMA and CD3 for the treatment of multiple myeloma
CN110114371A (en) * 2016-11-11 2019-08-09 奥托路斯有限公司 Chimeric antigen receptor
CA3044593A1 (en) * 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
EA201991168A1 (en) 2016-11-23 2019-12-30 Харпун Терапьютикс, Инк. PROTEIN BINDING PROSTATIC SPECIFIC MEMBRANE ANTIGEN
BR112019010602A2 (en) 2016-11-23 2019-12-17 Harpoon Therapeutics Inc trispecific psma proteins and methods of use
CN110352068A (en) 2016-12-02 2019-10-18 南加利福尼亚大学 The immunity receptor and its application method of synthesis
EP3559035A1 (en) 2016-12-21 2019-10-30 TeneoBio, Inc. Anti-bcma heavy chain-only antibodies
CN110582509A (en) 2017-01-31 2019-12-17 诺华股份有限公司 Cancer treatment with multispecific chimeric T cell receptor proteins
JP7257323B2 (en) * 2017-02-10 2023-04-13 ドラゴンフライ セラピューティクス， インコーポレイテッド Proteins that bind BCMA, NKG2D and CD16
AU2018222749B2 (en) 2017-02-17 2024-04-18 Fred Hutchinson Cancer Center Combination therapies for treatment of BCMA-related cancers and autoimmune disorders
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
CN110382539B (en) 2017-02-28 2023-08-08 阿菲姆德股份有限公司 Tandem diabodies for CD16A directed NK cell binding
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
CN110891974B (en) 2017-05-12 2021-08-06 哈普恩治疗公司 mesothelin binding protein
AU2018265860B2 (en) 2017-05-12 2022-08-11 Harpoon Therapeutics, Inc. MSLN targeting trispecific proteins and methods of use
EP3642236A1 (en) 2017-06-20 2020-04-29 TeneoOne, Inc. Anti-bcma heavy chain-only antibodies
WO2018237037A2 (en) * 2017-06-20 2018-12-27 Teneobio, Inc. HEAVY CHAIN ANTIBODY ONLY ANTI-BCMA
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. Chimeric antibody immune effctor cell engagers and methods of use thereof
TWI844073B (en) 2017-08-03 2024-06-01 美商安進公司 Interleukin-21 muteins and methods of treatment
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. Multispecific molecules that bind to bcma and uses thereof
RS65380B1 (en) 2017-08-24 2024-04-30 Novo Nordisk As Glp-1 compositions and uses thereof
EP3679040B1 (en) 2017-09-08 2022-08-03 Amgen Inc. Inhibitors of kras g12c and methods of using the same
EP3694878A1 (en) 2017-09-14 2020-08-19 GlaxoSmithKline Intellectual Property Development Limited Combination treatment for cancer
CN111094353A (en) 2017-09-14 2020-05-01 葛兰素史密斯克莱知识产权发展有限公司 Combination therapy for cancer
JP2020533383A (en) 2017-09-14 2020-11-19 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Combination treatment of cancer
EP3694997A4 (en) 2017-10-12 2021-06-30 Mcmaster University Y182T MUTATION T-LYMPHOCYTE ANTIGEN COUPLER AND METHODS AND USES THEREOF
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B cell maturation antigen binding proteins
CA3078969A1 (en) 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
AU2018351050B2 (en) 2017-10-18 2025-09-18 Novartis Ag Compositions and methods for selective protein degradation
FI3703750T3 (en) 2017-11-01 2025-02-07 Juno Therapeutics Inc Chimeric antigen receptors specific for b-cell maturation antigen and encoding polynucleotides
JP7256197B2 (en) 2017-11-01 2023-04-11 ジュノー セラピューティクス インコーポレイテッド Antibodies and chimeric antigen receptors specific for B-cell maturation antigens
SG11202003427XA (en) 2017-11-06 2020-05-28 Juno Therapeutics Inc Combination of a cell therapy and a gamma secretase inhibitor
JP2021502979A (en) 2017-11-15 2021-02-04 ノバルティス アーゲー BCMA targeting chimeric antigen receptor, CD19 targeting chimeric antigen receptor and combination therapy
RU2020121458A (en) 2017-11-30 2021-12-30 Новартис Аг CHIMERIC ANTIGEN RECEPTOR TARGETING BCMA AND ITS APPLICATIONS
WO2019126756A1 (en) 2017-12-22 2019-06-27 Teneobio, Inc. Heavy chain antibodies binding to cd22
CN111886250A (en) * 2017-12-27 2020-11-03 特尼奥生物股份有限公司 CD3-delta/epsilon heterodimer specific antibody
EP3732202A4 (en) 2017-12-28 2022-06-15 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against tigit
US20200368268A1 (en) 2018-01-08 2020-11-26 Novartis Ag Immune-enhancing rnas for combination with chimeric antigen receptor therapy
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
JP2019122373A (en) 2018-01-12 2019-07-25 アムジエン・インコーポレーテツド Anti-pd-1 antibodies and methods of treatment
WO2019137541A1 (en) 2018-01-15 2019-07-18 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against pd-1
ES2980171T3 (en) 2018-01-23 2024-09-30 Nextcure Inc B7-H4 antibodies and methods of using them
CA3090249A1 (en) 2018-01-31 2019-08-08 Novartis Ag Combination therapy using a chimeric antigen receptor
EP3752203A1 (en) 2018-02-13 2020-12-23 Novartis AG Chimeric antigen receptor therapy in combination with il-15r and il15
WO2019166650A1 (en) 2018-03-02 2019-09-06 Cdr-Life Ag Trispecific antigen binding proteins
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
CN116514995A (en) * 2018-04-12 2023-08-01 上海赛比曼生物科技有限公司 Chimeric antigen receptor targeting BCMA and preparation method and application thereof
CN113880952A (en) * 2018-04-13 2022-01-04 艾菲默德有限责任公司 Natural killer cell-conjugated antibody fusion constructs
BR112020023330A2 (en) 2018-05-14 2021-04-20 Harpoon Therapeutics, Inc. binding portion for conditional activation of immunoglobulin molecules
MA52632A (en) 2018-05-16 2021-09-15 Janssen Biotech Inc BCMA / CD3 AND GPRDC5D / CD3 BISPECIFIC ANTIBODIES FOR USE IN THE TREATMENT OF CANCER
CA3098420A1 (en) 2018-06-01 2019-12-05 Novartis Ag Binding molecules against bcma and uses thereof
US12371497B2 (en) 2018-06-08 2025-07-29 Imaginab, Inc. Antigen binding constructs to CD4
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
US11110123B2 (en) 2018-07-17 2021-09-07 Triumvira Immunologics Usa, Inc. T cell-antigen coupler with various construct optimizations
TWI838389B (en) 2018-07-19 2024-04-11 美商再生元醫藥公司 BISPECIFIC ANTI-BCMAxANTI-CD3 ANTIBODIES AND USES THEREOF
HUE066474T2 (en) 2018-07-19 2024-08-28 Regeneron Pharma Chimeric antigen receptors with BCMA specificity and their application
CN112351997B (en) 2018-07-20 2023-05-26 坦尼奥第二公司 Heavy chain antibodies that bind CD19
WO2020025596A1 (en) 2018-07-31 2020-02-06 Amgen Research (Munich) Gmbh Dosing regimen for bcma-cd3 bispecific antibodies
BR112021002072A2 (en) 2018-08-08 2021-06-01 Dragonfly Therapeutics, Inc. multispecific binding proteins that bind to bcma, nkg2d and cd16, and methods of use
RS65658B1 (en) * 2018-08-27 2024-07-31 Affimed Gmbh CRYOPRESERVED NK CELLS PRE-FILLED WITH ANTIBODY CONSTRUCT
CN119264211A (en) 2018-08-27 2025-01-07 瑞泽恩制药公司 Application of Raman spectroscopy in downstream purification
SG11202101825QA (en) 2018-08-31 2021-03-30 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US20210171909A1 (en) 2018-08-31 2021-06-10 Novartis Ag Methods of making chimeric antigen receptor?expressing cells
JP7605734B2 (en) 2018-08-31 2024-12-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Administration strategies to reduce cytokine release syndrome with CD3/C20 bispecific antibodies
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
SG11202103022WA (en) 2018-09-25 2021-04-29 Harpoon Therapeutics Inc Dll3 binding proteins and methods of use
WO2020069303A1 (en) 2018-09-28 2020-04-02 Amgen Inc. Antibodies against soluble bcma
CN109503716B (en) * 2018-10-08 2021-04-27 浙江生研生物科技有限公司 A bispecific chimeric antigen receptor molecule and its application in tumor therapy
BR112021008055A2 (en) 2018-10-31 2021-08-10 Glaxosmithkline Intellectual Property Development Limited methods for determining cancer prognosis in a patient, for predicting a patient's response to treatment with a bcma antigen binding protein, for selecting the dose of a bcma antigen binding protein, and for diagnosing cancer, pharmaceutical compositions, kit and use of a bcma antigen-binding protein to treat cancer
CN111138542B (en) 2018-11-01 2022-09-23 山东新时代药业有限公司 Bispecific antibodies and their uses
SG11202109061YA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Multifunctional molecules that bind to t cell related cancer cells and uses thereof
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
WO2020176397A1 (en) 2019-02-25 2020-09-03 Novartis Ag Mesoporous silica particles compositions for viral delivery
WO2020191316A1 (en) 2019-03-21 2020-09-24 Novartis Ag Car-t cell therapies with enhanced efficacy
US11964016B2 (en) 2019-03-21 2024-04-23 Regeneron Pharmaceuticals, Inc. Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy
CR20210500A (en) 2019-04-05 2021-11-05 Teneobio Inc Heavy chain antibodies binding to psma
WO2020210678A1 (en) 2019-04-12 2020-10-15 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US20220251152A1 (en) 2019-04-24 2022-08-11 Novartis Ag Compositions and methods for selective protein degradation
US12221481B2 (en) 2019-05-21 2025-02-11 Novartis Ag CD19 binding molecules and uses thereof
EP3983438A1 (en) 2019-06-14 2022-04-20 TeneoBio, Inc. Multispecific heavy chain antibodies binding to cd22 and cd3
CN114286828A (en) * 2019-06-24 2022-04-05 诺华股份有限公司 Dosing regimens and combination therapies for multispecific antibodies targeting B-cell maturation antigens
CN112204135A (en) * 2019-07-06 2021-01-08 苏州克睿基因生物科技有限公司 Immune cell expressing CD3 antibody receptor complex and application thereof
WO2021004400A1 (en) * 2019-07-06 2021-01-14 苏州克睿基因生物科技有限公司 Immune cell expressing cd3 antibody-receptor complex and use thereof
PH12022550277A1 (en) 2019-08-06 2022-11-21 Glaxosmithkline Ip Dev Ltd Biopharmacuetical compositions and related methods
CA3149585A1 (en) * 2019-09-25 2021-04-01 Bahram VALMEHR Multi-targeting effector cells and use thereof
US20240052048A1 (en) * 2019-10-10 2024-02-15 Suzhou Qin Pharmaceuticals Co., Ltd. Humanized monoclonal antibody targeting bcma and having human monkey cross-reactivity
RS65943B1 (en) 2019-11-11 2024-10-31 Amgen Res Munich Gmbh Dosing regimen for anti-bcma agents
KR20220105664A (en) 2019-11-26 2022-07-27 노파르티스 아게 Chimeric antigen receptors that bind BCMA and CD19 and uses thereof
CN115135305B (en) 2020-02-18 2025-09-12 诺和诺德股份有限公司 pharmaceutical preparations
BR112022016550A2 (en) 2020-02-21 2022-11-16 Harpoon Therapeutics Inc FLT3-BINDING PROTEINS AND METHODS OF USE
WO2021173995A2 (en) 2020-02-27 2021-09-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US20230256017A1 (en) 2020-02-27 2023-08-17 Jennifer Brogdon Methods of making chimeric antigen receptor-expressing cells
EP4121459A1 (en) 2020-03-19 2023-01-25 Amgen Inc. Antibodies against mucin 17 and uses thereof
JP7625007B2 (en) 2020-04-29 2025-01-31 テネオバイオ， インコーポレイテッド Multispecific heavy chain antibodies having modified heavy chain constant regions
UY40003A (en) 2020-04-29 2023-03-31 Teneobio Inc Multispecific heavy chain antibodies with modified heavy chain constant regions
PH12022553023A1 (en) 2020-05-11 2024-03-04 Janssen Biotech Inc Methods for treating multiple myeloma
EP4153317A1 (en) 2020-05-19 2023-03-29 Janssen Biotech, Inc. Compositions comprising a t cell redirection therapeutic and a vla-4 adhesion pathway inhibitor
CA3185455A1 (en) 2020-06-11 2021-12-16 Novartis Ag Zbtb32 inhibitors and uses thereof
IL299027A (en) 2020-06-30 2023-02-01 Teneobio Inc Multi-specific antibodies binding to bcma
IL300489A (en) 2020-08-21 2023-04-01 Novartis Ag Compositions and methods for in vivo generation of car expressing cells
JP2023542257A (en) 2020-09-16 2023-10-05 アムジェン インコーポレイテッド Method of administering therapeutic doses of bispecific T cell inducing molecules for the treatment of cancer
US20250136704A1 (en) 2020-11-10 2025-05-01 Amgen Inc. Methods for administering a bcmaxcd3 binding molecule
CN114573703A (en) * 2020-12-02 2022-06-03 康诺亚生物医药科技（成都）有限公司 Development and application of T cell adaptor therapeutic agent
WO2022135468A1 (en) * 2020-12-23 2022-06-30 信达生物制药(苏州)有限公司 Anti-bcma×cd3 bispecific antibody and use thereof
CN114763383B (en) * 2021-01-13 2024-12-17 博生吉医药科技(苏州)有限公司 Monoclonal antibody targeting human BCMA and application thereof
RS66868B1 (en) 2021-01-28 2025-06-30 Regeneron Pharma Compositions and methods for treating cytokine release syndrome
CA3214757A1 (en) 2021-04-08 2022-10-13 Andreas Loew Multifuntional molecules binding to tcr and uses thereof
CN118056008A (en) 2021-04-27 2024-05-17 诺华股份有限公司 Virus vector production system
BR112023024804A2 (en) 2021-05-28 2024-02-15 Glaxosmithkline Ip Dev Ltd COMBINATION THERAPIES TO TREAT CANCER
US12016923B2 (en) 2021-06-01 2024-06-25 Triumvira Immunologics Usa, Inc. Claudin 18.2 T cell-antigen couplers and uses thereof
CN115521381B (en) * 2021-06-24 2024-10-29 益科思特(北京)医药科技发展有限公司 Bispecific antibody binding to BCMA and CD3, and preparation method and application thereof
US11453723B1 (en) 2021-06-25 2022-09-27 Mcmaster University BCMA T cell-antigen couplers and uses thereof
WO2023012669A2 (en) 2021-08-03 2023-02-09 Glaxosmithkline Intellectual Property Development Limited Biopharmaceutical compositions and stable isotope labeling peptide mapping method
TW202323521A (en) 2021-08-20 2023-06-16 瑞士商諾華公司 Methods of making chimeric antigen receptor-expressing cells
EP4412713A1 (en) 2021-10-05 2024-08-14 GlaxoSmithKline Intellectual Property Development Ltd Combination therapies for treating cancer
US12098210B2 (en) 2021-11-03 2024-09-24 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of BCMAxCD3 bispecific antibodies
CN118591560A (en) 2022-01-25 2024-09-03 葛兰素史密斯克莱知识产权发展有限公司 Combination therapy for cancer
IL316002A (en) 2022-04-11 2024-11-01 Regeneron Pharma Universal tumor cell killing compositions and methods
AU2023369684A1 (en) 2022-10-26 2025-04-17 Novartis Ag Lentiviral formulations
EP4630454A1 (en) 2022-12-05 2025-10-15 GlaxoSmithKline Intellectual Property Development Ltd Methods of treatment using b-cell maturation antigen antagonists
US20240277844A1 (en) 2023-02-17 2024-08-22 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies
TW202440636A (en) 2023-03-21 2024-10-16 美商傳記５５有限公司 Cd19/cd38 multispecific antibodies
EP4626447A1 (en) 2023-03-31 2025-10-08 AbelZeta Inc. Bispecific chimeric antigen receptors targeting cd20 and bcma
WO2024215708A2 (en) * 2023-04-11 2024-10-17 AbelZeta Inc. Bispecific chimeric antigen receptors targeting bcma and cd19
WO2024246086A1 (en) 2023-06-01 2024-12-05 F. Hoffmann-La Roche Ag Immunostimulatory antigen binding molecules that specifically bind to bcma
TW202504918A (en) 2023-06-01 2025-02-01 瑞士商赫孚孟拉羅股份公司 Bispecific antibodies targeting bcma and cd28
WO2025160324A2 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
WO2025160340A2 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
US20250262300A1 (en) 2024-02-16 2025-08-21 Kite Pharma, Inc. Systems, methods, and kits for generating and administering engineered t cells and cd38 targeting compounds as a combination therapy
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response

Family Cites Families (215)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013A (en) 1847-03-13 Improvement in apparatus for the manufacture of malleable iron
US2003A (en) 1841-03-12 Improvement in horizontal windivhlls
US556A (en) 1838-01-09 Machine foe
US567A (en) 1838-01-09 Machine for r-uibbii
US4816A (en) 1846-10-17 Bell machinery for hotels
US1985A (en) 1841-02-18 Charles m
US70185A (en) 1867-10-29 fan oh be
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
US4281061A (en) 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0088046B1 (en) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipids in the aqueous phase
US4475916A (en) 1982-03-18 1984-10-09 Merck & Co., Inc. Osmotic drug delivery system
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4694778A (en) 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
JPS6147500A (en) 1984-08-15 1986-03-07 Res Dev Corp Of Japan Chimeric monoclonal antibody and its production method
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
DE3675588D1 (en) 1985-06-19 1990-12-20 Ajinomoto Kk HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE).
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ATE168272T1 (en) 1989-10-27 1998-08-15 Arch Dev Corp COMPOSITIONS AND THEIR USE FOR PROMOTING IMMUNOPOTENTIATION
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
ATE139258T1 (en) 1990-01-12 1996-06-15 Cell Genesys Inc GENERATION OF XENOGENE ANTIBODIES
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
JP2938569B2 (en) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド Method for producing xenogeneic immunoglobulin and transgenic mouse
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
AU664976B2 (en) 1990-08-29 1995-12-14 Gene Pharming Europe Bv Homologous recombination in mammalian cells
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0575319T3 (en) 1991-03-11 2000-07-10 Univ Georgia Res Found Cloning and expression of Renilla luciferase
WO1992022670A1 (en) 1991-06-12 1992-12-23 Genpharm International, Inc. Early detection of transgenic embryos
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5981175A (en) 1993-01-07 1999-11-09 Genpharm Internation, Inc. Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome
WO1995007463A1 (en) 1993-09-10 1995-03-16 The Trustees Of Columbia University In The City Of New York Uses of green fluorescent protein
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6037453A (en) 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
AU6113396A (en) 1995-06-14 1997-01-15 Regents Of The University Of California, The Novel high affinity human antibodies to tumor antigens
DK1143006T3 (en) 1995-08-18 2008-07-14 Morphosys Ip Gmbh Vectors / DNA sequences from human combinatorial antibody libraries
EP1916300A1 (en) 1995-08-29 2008-04-30 Kirin Pharma Kabushiki Kaisha Chimeric animal and method for producing the same
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
PT942968E (en) 1996-12-03 2008-03-27 Amgen Fremont Inc Fully human antibodies that bind egfr
EP1015872B1 (en) 1996-12-12 2005-03-02 Prolume, Ltd. Apparatus and method for detecting and identifying infectious agents
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
WO1999016499A1 (en) 1997-10-01 1999-04-08 Boston Scientific Corporation Dilation systems and related methods
NZ507381A (en) 1998-04-21 2003-12-19 Micromet Ag CD19xCD3 specific polypeptides and uses thereof
DE69942148D1 (en) 1998-06-22 2010-04-29 Immunomedics Inc USE OF BISPECIFIC ANTIBODIES IN DIAGNOSIS AND THERAPY
AU5728999A (en) 1998-07-28 2000-02-21 Micromet Ag Heterominibodies
ES2278463T3 (en) 1998-12-08 2007-08-01 Biovation Limited METHOD TO REDUCE THE IMMUNOGENICITY OF PROTEINS.
DK1141274T4 (en) 1999-01-07 2015-01-19 Zymogenetics Inc Soluble receptor BR43x2 and method of use thereof in therapy
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
NZ517782A (en) 1999-08-17 2004-01-30 Biogen Inc A beta-cell activating factor receptor belonging to the TNF family is used as a pharmaceutical agent and in the treatment of disease
UA74798C2 (en) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Method for treating cancer in mammals using polypeptide interfering with interaction between april and its receptors
WO2001087979A2 (en) 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
EP1399483B1 (en) 2001-01-05 2010-04-14 Pfizer Inc. Antibodies to insulin-like growth factor i receptor
AU2002238052A1 (en) 2001-02-20 2002-09-04 Zymogenetics, Inc. Antibodies that bind both bcma and taci
WO2002100348A2 (en) 2001-06-13 2002-12-19 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (egfr)
AR039067A1 (en) 2001-11-09 2005-02-09 Pfizer Prod Inc ANTIBODIES FOR CD40
ES2645563T3 (en) 2001-11-30 2017-12-05 Amgen Fremont Inc. Transgenic animals that carry human Ig light chain genes
ES2401428T3 (en) 2002-04-10 2013-04-19 Genentech, Inc. Anti-HER2 antibody variants
AU2003223683A1 (en) 2002-04-22 2003-11-03 Georgetown University Peripheral-type benzodiazepine receptor expression level as an index of organ damage and regeneration
WO2004106381A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
US7919089B2 (en) 2003-05-31 2011-04-05 Micromet Ag Pharmaceutical composition comprising a bispecific antibody for EpCAM
WO2004106380A2 (en) 2003-05-31 2004-12-09 Micromet Ag Human-anti-human cd3 binding molecules
PL1673398T3 (en) 2003-10-16 2011-05-31 Amgen Res Munich Gmbh Multispecific deimmunized cd3-binders
US20050142133A1 (en) 2003-12-03 2005-06-30 Xencor, Inc. Optimized proteins that target the epidermal growth factor receptor
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
US20050249723A1 (en) 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
JP4541014B2 (en) 2004-01-13 2010-09-08 キヤノンアネルバ株式会社 Plasma assisted sputter deposition system
WO2005075511A1 (en) 2004-01-29 2005-08-18 Genentech, Inc. Variants of the extracellular domain of bcma and uses thereof
CN1950399A (en) * 2004-02-16 2007-04-18 麦克罗梅特股份公司 Less immunogenic binding molecules
JP4812748B2 (en) 2004-04-06 2011-11-09 ノビミューン エスアー Methods for treating autoimmune and inflammatory diseases
KR101266716B1 (en) 2004-06-03 2013-05-31 노비뮨 에스 에이 Anti-cd3 antibodies and methods of use thereof
EP1778728A2 (en) 2004-08-19 2007-05-02 Genentech, Inc. Polypeptide variants with altered effector function
SG162788A1 (en) 2005-06-14 2010-07-29 Amgen Inc Self-buffering protein formulations
EP1904105A4 (en) 2005-07-11 2010-02-17 Macrogenics Inc Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
WO2007033230A2 (en) 2005-09-12 2007-03-22 Novimmune S.A. Anti-cd3 antibody formulations
CN101370830A (en) * 2005-09-26 2009-02-18 米德列斯公司 Human monoclonal antibodies to CD70
JP5686953B2 (en) 2005-10-11 2015-03-18 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー Compositions comprising cross-species-specific antibodies and uses of the compositions
US20090226466A1 (en) 2005-11-03 2009-09-10 Sherman Fong Therapeutic anti-her2 antibody fusion polypeptides
US9726673B2 (en) 2005-11-23 2017-08-08 Genentech, Inc. Methods and compositions related to B cell assays
US20070264687A1 (en) 2005-12-15 2007-11-15 Min-Yuan Chou Recombinant triplex scaffold-based polypeptides
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
WO2007146968A2 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
CN101675077B (en) 2007-04-03 2013-09-04 安进研发（慕尼黑）股份有限公司 Bispecific binders with cross-species specificity
US20230357444A1 (en) 2007-04-03 2023-11-09 Amgen Research (Munich) Gmbh Cross-species-specific binding domain
MX2009010610A (en) 2007-04-03 2010-06-08 Micromet Ag Cross-species-specific cd3-epsilon binding domain.
AU2008234020B2 (en) 2007-04-03 2013-02-07 Amgen Research (Munich) Gmbh Cross-species-specific CD3-epsilon binding domain
WO2008131242A1 (en) 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
US7998018B2 (en) 2007-04-30 2011-08-16 GM Global Technology Operations LLC Multi-speed transmission
US20090252729A1 (en) 2007-05-14 2009-10-08 Farrington Graham K Single-chain Fc (scFc) regions, binding polypeptides comprising same, and methods related thereto
WO2009132058A2 (en) * 2008-04-25 2009-10-29 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
MX338038B (en) 2008-10-01 2016-03-30 Amgen Res Munich Gmbh Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody.
SI2356153T1 (en) 2008-10-01 2016-07-29 Amgen Research (Munich) Gmbh Cross-species-specific psmaxcd3 bispecific single chain antibody
EP3375790A1 (en) 2008-10-01 2018-09-19 Amgen Research (Munich) GmbH Cross-species-specific single domain bispecific single chain antibody
HUE027499T2 (en) 2008-10-01 2016-10-28 Amgen Res Munich Gmbh Bispecific single chain antibodies specific for high molecular weight target antigens
JP2012509658A (en) 2008-11-26 2012-04-26 グラクソ グループ リミテッド Ligand binding to IL-13
NZ612647A (en) * 2009-03-10 2015-03-27 Biogen Idec Inc Anti-bcma antibodies
ES2708124T3 (en) 2009-04-27 2019-04-08 Oncomed Pharm Inc Procedure for preparing heteromultimeric molecules
UY32979A (en) 2009-10-28 2011-02-28 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
US20130129723A1 (en) 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
EP3165540A1 (en) 2010-04-13 2017-05-10 Celldex Therapeutics, Inc. Antibodies that bind human cd27 and uses thereof
JP6200806B2 (en) 2010-05-21 2017-09-20 メリマック ファーマシューティカルズ インコーポレーティッド Bispecific fusion protein
US9410994B2 (en) 2010-11-15 2016-08-09 Lg Electronics Inc. Refrigerator and operation method thereof
EP3974453A3 (en) * 2010-11-16 2022-08-03 Amgen Inc. Agents and methods for treating diseases that correlate with bcma expression
KR102447595B1 (en) 2010-11-30 2022-09-26 추가이 세이야쿠 가부시키가이샤 Cell injury induction therapy
US9409950B2 (en) 2010-12-23 2016-08-09 Biogen Ma Inc. Linker peptides and polypeptides comprising same
CN106279418A (en) 2011-05-27 2017-01-04 葛兰素集团有限公司 BCMA(CD269/TNFRSF17) associated proteins
EP2748201B1 (en) 2011-08-23 2017-12-13 Roche Glycart AG Bispecific t cell activating antigen binding molecules
WO2013026837A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
TWI679212B (en) 2011-11-15 2019-12-11 美商安進股份有限公司 Binding molecules for e3 of bcma and cd3
AU2013289883B2 (en) 2012-07-13 2018-11-01 Zymeworks Bc Inc. Bispecific asymmetric heterodimers comprising anti-CD3 constructs
JOP20200236A1 (en) 2012-09-21 2017-06-16 Regeneron Pharma Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
EP2731280B8 (en) 2012-11-07 2019-03-20 Telefonaktiebolaget LM Ericsson (publ) Loopback-based built-in-self-test
TW201425336A (en) 2012-12-07 2014-07-01 Amgen Inc BCMA antigen binding proteins
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
WO2014110601A1 (en) 2013-01-14 2014-07-17 Xencor, Inc. Novel heterodimeric proteins
JO3519B1 (en) 2013-01-25 2020-07-05 Amgen Inc Antibody combinations for CDH19 and CD3
WO2014122143A1 (en) 2013-02-05 2014-08-14 Engmab Ag Method for the selection of antibodies against bcma
EP2762497A1 (en) 2013-02-05 2014-08-06 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
US9458245B2 (en) 2013-03-06 2016-10-04 Merrimack Pharmaceuticals, Inc. ANTI-C-MET tandem Fc bispecific antibodies
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
AR095374A1 (en) * 2013-03-15 2015-10-14 Amgen Res Munich Gmbh UNION MOLECULES FOR BCMA AND CD3
DK2970449T3 (en) 2013-03-15 2019-11-25 Amgen Res Munich Gmbh SINGLE-CHAINED BINDING MOLECULES COVERING N-TERMINAL ABP
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
EP3733710A1 (en) 2013-09-25 2020-11-04 Amgen, Inc Hetrodimeric v-c-fc-v-c antibody
MX377344B (en) 2014-07-31 2025-03-07 Amgen Res Munich Gmbh OPTIMIZED CROSS-SPECIES-SPECIFIC BISPECIFIC SINGLE-CHAIN ANTIBODY CONSTRUCTS.
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
SI3223845T1 (en) 2014-11-26 2021-11-30 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd20
SG10201909308XA (en) 2015-04-17 2019-11-28 Amgen Res Munich Gmbh Bispecific antibody constructs for cdh3 and cd3
TWI829617B (en) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Antibody constructs for flt3 and cd3
TWI793062B (en) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Antibody constructs for dll3 and cd3
TWI717375B (en) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Antibody constructs for cd70 and cd3
TWI744242B (en) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Antibody constructs for egfrviii and cd3
TWI796283B (en) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Antibody constructs for msln and cd3
CR20180418A (en) 2016-02-03 2019-01-15 Amgen Res Munich Gmbh BISPECPIFYING ANTIBODY STRUCTURES FOR PSMA AND CD3 THAT ARE LINKED TO T-CELLS
EA039859B1 (en) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Bispecific antibody constructs binding egfrviii and cd3
DK3411402T3 (en) 2016-02-03 2022-02-07 Amgen Res Munich Gmbh BCMA AND CD3 BISPECIFIC T-CELL INVOLVING ANTIBODY CONSTRUCTIONS
KR102687833B1 (en) 2016-11-02 2024-07-24 브리스톨-마이어스 스큅 컴퍼니 Combination use of dual specific antibodies and immunological drugs against BCMA and CD3 for the treatment of multiple myeloma
TWI868050B (en) 2017-05-05 2025-01-01 美商安進公司 Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration

Also Published As

Publication number Publication date
RS59373B1 (en) 2019-11-29
UY34453A (en) 2013-06-28
JP6231007B2 (en) 2017-11-15
US9150664B2 (en) 2015-10-06
DK2780375T3 (en) 2019-11-18
MX2014005852A (en) 2014-09-22
PL2780375T3 (en) 2020-01-31
MX2014005851A (en) 2015-01-19
IL260189A (en) 2018-07-31
KR102346029B1 (en) 2022-01-03
PH12014501076A1 (en) 2014-06-23
TW201326214A (en) 2013-07-01
KR102229469B1 (en) 2021-03-18
CA2850591A1 (en) 2013-05-23
JP6738314B2 (en) 2020-08-12
EP2780374B1 (en) 2019-08-21
US20220064336A1 (en) 2022-03-03
US10766969B2 (en) 2020-09-08
JP2015504306A (en) 2015-02-12
US20130156770A1 (en) 2013-06-20
WO2013072415A1 (en) 2013-05-23
ME03521B (en) 2020-04-20
NZ622087A (en) 2016-06-24
ZA201401615B (en) 2017-08-30
JP2017195889A (en) 2017-11-02
LT2780375T (en) 2019-11-11
AU2012327203A1 (en) 2013-05-30
WO2013072406A1 (en) 2013-05-23
BR112014010630B1 (en) 2022-10-04
IL232603B (en) 2018-07-31
EA028162B1 (en) 2017-10-31
ECSP14004893A (en) 2015-06-30
UY34454A (en) 2013-06-28
BR112014010630A2 (en) 2017-04-25
KR20140105758A (en) 2014-09-02
MA35449B1 (en) 2014-09-01
SG11201401729PA (en) 2014-09-26
US20220251243A1 (en) 2022-08-11
GEP20186928B (en) 2018-11-26
PH12014501091A1 (en) 2014-07-28
PT2780375T (en) 2019-11-12
EP2780374A1 (en) 2014-09-24
HRP20191697T1 (en) 2019-12-13
KR20200003934A (en) 2020-01-10
CL2014001254A1 (en) 2014-10-10
ES2751996T3 (en) 2020-04-02
SMT201900627T1 (en) 2020-01-14
SG10201606484SA (en) 2016-10-28
AR088883A1 (en) 2014-07-16
KR20210032012A (en) 2021-03-23
US20140348837A1 (en) 2014-11-27
SI2780375T1 (en) 2019-11-29
US9598500B2 (en) 2017-03-21
EP4512481A2 (en) 2025-02-26
PE20141564A1 (en) 2014-11-29
KR102062231B1 (en) 2020-01-03
EP3623385A8 (en) 2020-05-06
US20220356268A1 (en) 2022-11-10
ECSP14004829A (en) 2015-07-31
EA201490932A1 (en) 2014-09-30
JP7250736B2 (en) 2023-04-03
US9340621B2 (en) 2016-05-17
AP2014007529A0 (en) 2014-03-31
JP2014534242A (en) 2014-12-18
CN104114578A (en) 2014-10-22
BR112014010940A2 (en) 2017-05-16
CY1122543T1 (en) 2021-01-27
US12281175B2 (en) 2025-04-22
SG10201704483RA (en) 2017-07-28
JP2020202838A (en) 2020-12-24
JP6378087B2 (en) 2018-08-22
EP4512481A3 (en) 2025-03-12
IL232636A0 (en) 2014-06-30
EP2780375A1 (en) 2014-09-24
EP3611193A1 (en) 2020-02-19
JP2018050627A (en) 2018-04-05
EP3623385A1 (en) 2020-03-18
TWI679212B (en) 2019-12-11
IL232603A0 (en) 2014-06-30
SG11201400671YA (en) 2014-04-28
TN2014000097A1 (en) 2015-07-01
EA201490931A1 (en) 2014-08-29
CA2849196C (en) 2021-04-20
CA2849196A1 (en) 2013-05-23
CN104169300A (en) 2014-11-26
CN109485729A (en) 2019-03-19
UA116766C2 (en) 2018-05-10
ES2749451T3 (en) 2020-03-20
TN2014000121A1 (en) 2015-07-01
MX349396B (en) 2017-07-26
CN104114578B (en) 2018-10-16
US20150023967A1 (en) 2015-01-22
US20130156769A1 (en) 2013-06-20
KR20140105757A (en) 2014-09-02
EP2780375B1 (en) 2019-09-11
HUE046682T2 (en) 2020-03-30
MA35450B1 (en) 2014-09-01
US12281176B2 (en) 2025-04-22
MY189544A (en) 2022-02-16

Similar Documents

Publication Publication Date Title
FR23C1013I1 (en) BINDING MOLECULES FOR BCMA AND CD3
ZA201505209B (en) Binding molecules for bcma and cd3
HUE041958T2 (en) 4-IBB binding molecules
EP2922566A4 (en) EGFR AND C-MET-FIBRONECTIN TYPE III BINDING MOLECULES
EP2723379A4 (en) ANTI-ALPHA SYNNUCLEIN BINDING MOLECULES
HRP20180893T1 (en) Antibodies and Other B7-H1 and PD-1 Binding Molecules
IL232726A0 (en) Binding molecules specific for her3 and uses thereof
EP2857419A4 (en) ANTIGEN BINDING MOLECULE REMOVING ANTIGEN ASSOCIATED WITH
RS58765B1 (en) CD3-BINDING MOLECULES ABOUT BINDING FOR HUMAN AND NON-HUMAN CD3
AP2015008266A0 (en) 1L-18 binding molecules
EP2895203A4 (en) ANTIGEN BINDING CONSTRUCTIONS FOR CD3
EP2678819A4 (en) SYSTEMS AND METHODS APPLYING TO EXTENSIONS FOR ELECTRONIC BOOKS
EP2766093A4 (en) USE OF SEMAPHORIN-4D BINDING MOLECULES TO MODULATE THE PERMEABILITY OF THE HEMATO-ENCEPHALIC BARRIER
EP2860500A4 (en) APPARATUS FOR PREVENTING COUNTERFEITING AND MODIFICATION
GB201219487D0 (en) Anti-S100A4 antibody molecules and their uses
IL232797A0 (en) Thrombin-binding antibody molecules and uses thereof
BR302012000184S1 (en) "LABORATORY APPLICATION SETUP"
GB201101801D0 (en) Binding molecule and method for measuring
HK40122420A (en) Binding molecules for bcma and cd3
AP2014007497A0 (en) Binding molecules for BCMA and CD3
HK1196375A (en) Binding molecules for bcma and cd3
GB201117182D0 (en) Anti-notch antibody molecules and uses thereof